OncoZenge AB (publ) (STO:ONCOZ)
Sweden · Delayed Price · Currency is SEK 6.90
-0.29 (-4.03%)
May 21, 2026, 12:30 PM CET
OncoZenge AB Revenue
In the year 2025, OncoZenge AB had annual revenue of 2.78M SEK with 278,300.00% growth. OncoZenge AB had revenue of 1,000.00 in the quarter ending December 31, 2025.
Revenue
2.78M
Revenue Growth
+278,300.00%
P/S Ratio
36.28
Revenue / Employee
2.78M
Employees
1
Market Cap
101.01M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.78M | 2.78M | 278,300.00% |
| Dec 31, 2024 | 1,000.00 | -2.00K | -66.67% |
| Dec 31, 2023 | 3.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Magle Chemoswed Holding AB | 287.55M |
| IRLAB Therapeutics AB | 92.46M |
| Alzinova AB | 25.66M |
| Scandinavian ChemoTech AB | 12.61M |
| Biovica International AB | 10.93M |
| AcouSort AB | 10.43M |
| NextCell Pharma AB | 9.83M |
| Spago Nanomedical AB | 4.38M |
OncoZenge AB News
- 3 months ago - OncoZenge AB Quarterly report: Q4 2025 - Filings
- 3 months ago - OncoZenge AB Annual report: Q4 2025 - Filings
- 7 months ago - OncoZenge AB Quarterly report: Q3 2025 - Filings
- 9 months ago - OncoZenge AB Quarterly report: Q2 2025 - Filings
- 5 years ago - OncoZenge AB Earnings Call Transcript: Q2 2021 - Transcripts